(Reuters) - Eli Lilly and Co's experimental pill for rheumatoid arthritis proved superior to Abbvie Inc's leading injectable Humira treatment in a large study, which analysts said could prod them to raise sales forecasts for the medicine.br clear='all'/img width='1' height='1' src='http://reuters.us.feedsportal.com/c/35217/f/654220/s/4aab6179/sc/19/mf.gif' border='0'/div class="feedflare"
a href="http://feeds.feedburner.com/~ff/reuters/scienceNews?a=afQKCbh7-FQ:Sdkf_OCXk8M:yIl2AUoC8zA"img src="http://feeds.feedburner.com/~ff/reuters/scienceNews?d=yIl2AUoC8zA" border="0"/img/a a href="http://feeds.feedburner.com/~ff/reuters/scienceNews?a=afQKCbh7-FQ:Sdkf_OCXk8M:F7zBnMyn0Lo"img src="http://feeds.feedburner.com/~ff/reuters/scienceNews?i=afQKCbh7-FQ:Sdkf_OCXk8M:F7zBnMyn0Lo" border="0"/img/a a href="http://feeds.feedburner.com/~ff/reuters/scienceNews?a=afQKCbh7-FQ:Sdkf_OCXk8M:V_sGLiPBpWU"img src="http://feeds.feedburner.com/~ff/reuters/scienceNews?i=afQKCbh7-FQ:Sdkf_OCXk8M:V_sGLiPBpWU" border="0"/img/a
/divimg src="http://feeds.feedburner.com/~r/reuters/scienceNews/~4/afQKCbh7-FQ" height="1" width="1" alt=""/